Skip to main content

Advertisement

Log in

Trastuzumab and breast cancer: developments and current status

  • REVIEW ARTICLE
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

The emergence of trastuzumab has drastically changed therapy for breast cancer. Trastuzumab (Herceptin; Genentech) is a recombinant humanized monoclonal antibody that targets an epitope in the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a member of a family of four transmembrane receptor tyrosine kinases that regulate cell growth, survival, and differentiation via multiple signal transduction pathways. Overexpression of HER2 or amplification of the HER2 gene occurs in 20%–30% of human breast cancers. Preclinical models have demonstrated that this antibody has significant antitumor activity as a single agent, and it also has a synergy with certain chemotherapeutic drugs. Phase II and III clinical trials performed in women with metastatic breast cancers that overexpress HER2 have shown trastuzumab to have clinical activity when used as monotherapy, while also improving survival when used as a first-line therapy in combination with chemotherapy. At present, clinical investigations are focusing attention on the efficacy of trastuzumab in both the adjuvant and neoadjuvant setting, as well as in the metastatic setting. In this review, we describe the developments and current status of trastuzumab-based treatment for breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Y Yarden MX Sliwkowski (2001) ArticleTitleUntangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127–137 Occurrence Handle11252954 Occurrence Handle1:CAS:528:DC%2BD3MXivVWnt7k%3D Occurrence Handle10.1038/35052073

    Article  PubMed  CAS  Google Scholar 

  2. DJ Slamon GM Clark SG Wong et al. (1987) ArticleTitleHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177–182 Occurrence Handle3798106 Occurrence Handle1:CAS:528:DyaL2sXhtVSht7s%3D

    PubMed  CAS  Google Scholar 

  3. DJ Slamon W Godolphin LA Jones et al. (1989) ArticleTitleStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707–712 Occurrence Handle2470152 Occurrence Handle1:STN:280:DyaL1M3kt1Wntg%3D%3D

    PubMed  CAS  Google Scholar 

  4. HB Muss AD Thor DA Berry et al. (1994) ArticleTitlec-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer N Engl J Med 330 1260–1266 Occurrence Handle7908410 Occurrence Handle1:STN:280:DyaK2c7psFensQ%3D%3D Occurrence Handle10.1056/NEJM199405053301802

    Article  PubMed  CAS  Google Scholar 

  5. S Paik J Bryant C Park et al. (1998) ArticleTitleerbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J Natl Cancer Inst 90 1361–1370 Occurrence Handle9747867 Occurrence Handle1:CAS:528:DyaK1cXmtlelurw%3D Occurrence Handle10.1093/jnci/90.18.1361

    Article  PubMed  CAS  Google Scholar 

  6. AD Thor DA Berry DR Budman et al. (1998) ArticleTitleerbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer J Natl Cancer Inst 90 1346–1360 Occurrence Handle9747866 Occurrence Handle1:CAS:528:DyaK1cXmtlelur4%3D Occurrence Handle10.1093/jnci/90.18.1346

    Article  PubMed  CAS  Google Scholar 

  7. S De Placido M De Laurentiis C Carlomagno et al. (2003) ArticleTitleTwenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer Clin Cancer Res 9 1039–1046 Occurrence Handle12631604 Occurrence Handle1:CAS:528:DC%2BD3sXhvFKit7c%3D

    PubMed  CAS  Google Scholar 

  8. CL Vogel MA Cobleigh D Tripathy et al. (2002) ArticleTitleEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719–726 Occurrence Handle11821453 Occurrence Handle1:CAS:528:DC%2BD38XhsVGmt7o%3D Occurrence Handle10.1200/JCO.20.3.719

    Article  PubMed  CAS  Google Scholar 

  9. DJ Slamon B Leyland-Jones S Shak et al. (2001) ArticleTitleUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783–792 Occurrence Handle11248153 Occurrence Handle1:CAS:528:DC%2BD3MXisVGktrc%3D Occurrence Handle10.1056/NEJM200103153441101

    Article  PubMed  CAS  Google Scholar 

  10. RM Hudziak GD Lewis M Winget et al. (1989) ArticleTitlep185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor Mol Cell Biol 9 1165–1172 Occurrence Handle2566907 Occurrence Handle1:CAS:528:DyaL1MXhvFSqs7g%3D

    PubMed  CAS  Google Scholar 

  11. RJ Pietras BM Fendly VR Chazin et al. (1994) ArticleTitleAntibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells Oncogene 9 1829–1838 Occurrence Handle7911565 Occurrence Handle1:CAS:528:DyaK2cXltVKhs78%3D

    PubMed  CAS  Google Scholar 

  12. HM Shepard GD Lewis JC Sarup et al. (1991) ArticleTitleMonoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic J Clin Immunol 11 117–127 Occurrence Handle1679763 Occurrence Handle1:CAS:528:DyaK3MXmsFent7w%3D Occurrence Handle10.1007/BF00918679

    Article  PubMed  CAS  Google Scholar 

  13. P Carter L Presta CM Gorman et al. (1992) ArticleTitleHumanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285–4289 Occurrence Handle1350088 Occurrence Handle1:CAS:528:DyaK3sXitFSqtb0%3D Occurrence Handle10.1073/pnas.89.10.4285

    Article  PubMed  CAS  Google Scholar 

  14. R Nahta FJ Esteva (2006) ArticleTitleHerceptin: mechanisms of action and resistance Cancer Lett 232 123–138 Occurrence Handle16458110 Occurrence Handle1:CAS:528:DC%2BD28XhtFWhurg%3D Occurrence Handle10.1016/j.canlet.2005.01.041

    Article  PubMed  CAS  Google Scholar 

  15. Y Yarden (2001) ArticleTitleThe EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities Eur J Cancer 37 IssueIDSuppl 4 S3–8 Occurrence Handle11597398 Occurrence Handle1:CAS:528:DC%2BD3MXntlOku78%3D Occurrence Handle10.1016/S0959-8049(01)00230-1

    Article  PubMed  CAS  Google Scholar 

  16. CH Yeon MD Pegram (2005) ArticleTitleAnti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer Invest New Drugs 23 391–409 Occurrence Handle16133791 Occurrence Handle1:CAS:528:DC%2BD2MXnvVSqsbc%3D Occurrence Handle10.1007/s10637-005-2899-8

    Article  PubMed  CAS  Google Scholar 

  17. M Pegram S Hsu G Lewis et al. (1999) ArticleTitleInhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 2241–2251 Occurrence Handle10327070 Occurrence Handle1:CAS:528:DyaK1MXis12murk%3D Occurrence Handle10.1038/sj.onc.1202526

    Article  PubMed  CAS  Google Scholar 

  18. MD Pegram GE Konecny C O'Callaghan et al. (2004) ArticleTitleRational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J Natl Cancer Inst 96 739–749 Occurrence Handle15150302 Occurrence Handle1:CAS:528:DC%2BD2cXkt1Sqsbo%3D

    PubMed  CAS  Google Scholar 

  19. J Baselga L Norton J Albanell et al. (1998) ArticleTitleRecombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts Cancer Res 58 2825–2831 Occurrence Handle9661897 Occurrence Handle1:CAS:528:DyaK1cXksFCqt7g%3D

    PubMed  CAS  Google Scholar 

  20. J Baselga D Tripathy J Mendelsohn et al. (1996) ArticleTitlePhase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 737–744 Occurrence Handle8622019 Occurrence Handle1:CAS:528:DyaK28Xit1Gjs7w%3D

    PubMed  CAS  Google Scholar 

  21. MA Cobleigh CL Vogel D Tripathy et al. (1999) ArticleTitleMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639–2648 Occurrence Handle10561337 Occurrence Handle1:CAS:528:DyaK1MXmtlWrurk%3D

    PubMed  CAS  Google Scholar 

  22. D Slamon M Pegram (2001) ArticleTitleRationale for trastuzumab (Herceptin) in adjuvant breast cancer trials Semin Oncol 28 13–19 Occurrence Handle11301370 Occurrence Handle1:CAS:528:DC%2BD3MXjtFWqsr8%3D Occurrence Handle10.1016/S0093-7754(01)90188-5

    Article  PubMed  CAS  Google Scholar 

  23. AD Seidman MN Fornier FJ Esteva et al. (2001) ArticleTitleWeekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification J Clin Oncol 19 2587–2595 Occurrence Handle11352950 Occurrence Handle1:CAS:528:DC%2BD3MXkt1Omurk%3D

    PubMed  CAS  Google Scholar 

  24. FJ Esteva V Valero D Booser et al. (2002) ArticleTitlePhase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer J Clin Oncol 20 1800–1808 Occurrence Handle11919237 Occurrence Handle1:CAS:528:DC%2BD38XjtFGqsrw%3D Occurrence Handle10.1200/JCO.2002.07.058

    Article  PubMed  CAS  Google Scholar 

  25. M Marty F Cognetti D Maraninchi et al. (2005) ArticleTitleRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265–4274 Occurrence Handle15911866 Occurrence Handle1:CAS:528:DC%2BD2MXms12gs70%3D Occurrence Handle10.1200/JCO.2005.04.173

    Article  PubMed  CAS  Google Scholar 

  26. F Montemurro G Choa R Faggiuolo et al. (2004) ArticleTitleA phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer Oncology 66 38–45 Occurrence Handle15031597 Occurrence Handle1:CAS:528:DC%2BD2cXitlyitLg%3D Occurrence Handle10.1159/000076333

    Article  PubMed  CAS  Google Scholar 

  27. KL Tedesco AD Thor DH Johnson et al. (2004) ArticleTitleDocetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial J Clin Oncol 22 1071–1077 Occurrence Handle15020608 Occurrence Handle1:CAS:528:DC%2BD2cXptlCku7w%3D Occurrence Handle10.1200/JCO.2004.10.046

    Article  PubMed  CAS  Google Scholar 

  28. MD Pegram A Lipton DF Hayes et al. (1998) ArticleTitlePhase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J Clin Oncol 16 2659–2671 Occurrence Handle9704716 Occurrence Handle1:CAS:528:DyaK1cXlsFCgurs%3D

    PubMed  CAS  Google Scholar 

  29. MD Pegram T Pienkowski DW Northfelt et al. (2004) ArticleTitleResults of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer J Natl Cancer Inst 96 759–769 Occurrence Handle15150304 Occurrence Handle1:CAS:528:DC%2BD2cXkt1Sqsbg%3D Occurrence Handle10.1093/jnci/djh133

    Article  PubMed  CAS  Google Scholar 

  30. HJ Stemmler S Kahlert O Brudler et al. (2005) ArticleTitleHigh efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study Clin Oncol (R Coll Radiol) 17 630–635 Occurrence Handle1:STN:280:DC%2BD2MnosValtQ%3D%3D

    CAS  Google Scholar 

  31. EA Perez VJ Suman KM Rowland et al. (2005) ArticleTitleTwo concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252 Clin Breast Cancer 6 425–432 Occurrence Handle16381626 Occurrence Handle1:CAS:528:DC%2BD28XosVOlsg%3D%3D

    PubMed  CAS  Google Scholar 

  32. C Nistico C Garufi M Milella et al. (2000) ArticleTitleWeekly schedule of vinorelbine in pretreated breast cancer patients Breast Cancer Res Treat 59 223–229 Occurrence Handle10832592 Occurrence Handle1:CAS:528:DC%2BD3cXjvVCltLw%3D Occurrence Handle10.1023/A:1006390700480

    Article  PubMed  CAS  Google Scholar 

  33. A Romero MG Rabinovich CT Vallejo et al. (1994) ArticleTitleVinorelbine as first-line chemotherapy for metastatic breast carcinoma J Clin Oncol 12 336–341 Occurrence Handle8113840 Occurrence Handle1:STN:280:DyaK2c7lslKisw%3D%3D

    PubMed  CAS  Google Scholar 

  34. HJ Burstein LN Harris PK Marcom et al. (2003) ArticleTitleTrastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm J Clin Oncol 21 2889–2895 Occurrence Handle12885806 Occurrence Handle1:CAS:528:DC%2BD2cXpsVKjtro%3D Occurrence Handle10.1200/JCO.2003.02.018

    Article  PubMed  CAS  Google Scholar 

  35. HJ Burstein I Kuter SM Campos et al. (2001) ArticleTitleClinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer J Clin Oncol 19 2722–2730 Occurrence Handle11352965 Occurrence Handle1:CAS:528:DC%2BD3MXkt1Omu7k%3D

    PubMed  CAS  Google Scholar 

  36. M Jahanzeb JE Mortimer F Yunus et al. (2002) ArticleTitlePhase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer Oncologist 7 410–417 Occurrence Handle12401903 Occurrence Handle1:CAS:528:DC%2BD38XptVOgtL0%3D Occurrence Handle10.1634/theoncologist.7-5-410

    Article  PubMed  CAS  Google Scholar 

  37. MD Pegram RS Finn K Arzoo et al. (1997) ArticleTitleThe effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells Oncogene 15 537–547 Occurrence Handle9247307 Occurrence Handle1:CAS:528:DyaK2sXls1OltLc%3D Occurrence Handle10.1038/sj.onc.1201222

    Article  PubMed  CAS  Google Scholar 

  38. P Papaldo A Fabi G Ferretti et al. (2006) ArticleTitleA phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease Ann Oncol 17 630–636 Occurrence Handle16410363 Occurrence Handle1:STN:280:DC%2BD287mslSltg%3D%3D Occurrence Handle10.1093/annonc/mdj110

    Article  PubMed  CAS  Google Scholar 

  39. G Fountzilas E Razis D Tsavdaridis et al. (2003) ArticleTitleContinuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group Clin Breast Cancer 4 120–125 Occurrence Handle12864940 Occurrence Handle1:CAS:528:DC%2BD3sXmt1OlsrY%3D

    PubMed  CAS  Google Scholar 

  40. KA Gelmon J Mackey S Verma et al. (2004) ArticleTitleUse of trastuzumab beyond disease progression: observations from a retrospective review of case histories Clin Breast Cancer 5 52–58 Occurrence Handle15140285 Occurrence Handle1:CAS:528:DC%2BD2cXltFygsbk%3D

    PubMed  CAS  Google Scholar 

  41. HJ Stemmler S Kahlert W Siekiera et al. (2005) ArticleTitleProlonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC) Onkologie 28 582–586 Occurrence Handle16249644 Occurrence Handle1:CAS:528:DC%2BD2MXhtFCru7jM Occurrence Handle10.1159/000088296

    Article  PubMed  CAS  Google Scholar 

  42. D Tripathy DJ Slamon M Cobleigh et al. (2004) ArticleTitleSafety of treatment of metastatic breast cancer with trastuzumab beyond disease progression J Clin Oncol 22 1063–1070 Occurrence Handle15020607 Occurrence Handle1:CAS:528:DC%2BD2cXptlCku78%3D Occurrence Handle10.1200/JCO.2004.06.557

    Article  PubMed  CAS  Google Scholar 

  43. EH Romond EA Perez J Bryant et al. (2005) ArticleTitleTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673–1684 Occurrence Handle16236738 Occurrence Handle1:CAS:528:DC%2BD2MXhtFansr3F Occurrence Handle10.1056/NEJMoa052122

    Article  PubMed  CAS  Google Scholar 

  44. MJ Piccart-Gebhart M Procter B Leyland-Jones et al. (2005) ArticleTitleTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659–1672 Occurrence Handle16236737 Occurrence Handle1:CAS:528:DC%2BD2MXhtFansr3L Occurrence Handle10.1056/NEJMoa052306

    Article  PubMed  CAS  Google Scholar 

  45. D Slamon W Eiermann N Robert T Pienkowski et al. (2005) ArticleTitlePhase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study Breast Cancer Res Treat 94 IssueIDSuppl 1 S5

    Google Scholar 

  46. HJ Burstein LN Harris R Gelman et al. (2003) ArticleTitlePreoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study J Clin Oncol 21 46–53 Occurrence Handle12506169 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWru7g%3D Occurrence Handle10.1200/JCO.2003.03.124

    Article  PubMed  CAS  Google Scholar 

  47. AU Buzdar NK Ibrahim D Francis et al. (2005) ArticleTitleSignificantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676–3685 Occurrence Handle15738535 Occurrence Handle1:CAS:528:DC%2BD2MXlslWntr8%3D Occurrence Handle10.1200/JCO.2005.07.032

    Article  PubMed  CAS  Google Scholar 

  48. BP Coudert L Arnould L Moreau et al. (2006) ArticleTitlePre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial Ann Oncol 17 409–414 Occurrence Handle16332965 Occurrence Handle1:STN:280:DC%2BD287ht1OktA%3D%3D Occurrence Handle10.1093/annonc/mdj096

    Article  PubMed  CAS  Google Scholar 

  49. AE Van Pelt S Mohsin RM Elledge et al. (2003) ArticleTitleNeoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results Clin Breast Cancer 4 348–353 Occurrence Handle14715110 Occurrence Handle1:CAS:528:DC%2BD2cXotlOjtg%3D%3D

    PubMed  CAS  Google Scholar 

  50. C Wenzel D Hussian R Bartsch et al. (2004) ArticleTitlePreoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study J Cancer Res Clin Oncol 130 400–404 Occurrence Handle15168107 Occurrence Handle1:CAS:528:DC%2BD2cXltF2hs7g%3D Occurrence Handle10.1007/s00432-004-0559-6

    Article  PubMed  CAS  Google Scholar 

  51. N Cook-Bruns (2001) ArticleTitleRetrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer Oncology 61 IssueIDSuppl 2 58–66 Occurrence Handle11694789 Occurrence Handle1:CAS:528:DC%2BD3MXovFWjsLY%3D Occurrence Handle10.1159/000055403

    Article  PubMed  CAS  Google Scholar 

  52. DL Keefe (2002) ArticleTitleTrastuzumab-associated cardiotoxicity Cancer 95 1592–1600 Occurrence Handle12237930 Occurrence Handle1:CAS:528:DC%2BD38XnvV2qur8%3D Occurrence Handle10.1002/cncr.10854

    Article  PubMed  CAS  Google Scholar 

  53. A Seidman C Hudis MK Pierri et al. (2002) ArticleTitleCardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 1215–1221 Occurrence Handle11870163 Occurrence Handle1:CAS:528:DC%2BD38XisVWmuro%3D Occurrence Handle10.1200/JCO.20.5.1215

    Article  PubMed  CAS  Google Scholar 

  54. EA Perez R Rodeheffer (2004) ArticleTitleClinical cardiac tolerability of trastuzumab J Clin Oncol 22 322–329 Occurrence Handle14722042 Occurrence Handle1:CAS:528:DC%2BD2cXpsVKitLY%3D Occurrence Handle10.1200/JCO.2004.01.120

    Article  PubMed  CAS  Google Scholar 

  55. TH Grote LF Pineda RA Figlin et al. (1997) ArticleTitleOral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group Cancer J Sci Am 3 45–51 Occurrence Handle9072308 Occurrence Handle1:STN:280:DyaK2s3gsFKnsw%3D%3D

    PubMed  CAS  Google Scholar 

  56. SL Erickson KS O'Shea N Ghaboosi et al. (1997) ArticleTitleErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2- and heregulin-deficient mice Development 124 4999–5011 Occurrence Handle9362461 Occurrence Handle1:CAS:528:DyaK1cXjtV2jtQ%3D%3D

    PubMed  CAS  Google Scholar 

  57. KF Lee H Simon H Chen et al. (1995) ArticleTitleRequirement for neuregulin receptor erbB2 in neural and cardiac development Nature 378 394–398 Occurrence Handle7477377 Occurrence Handle1:CAS:528:DyaK2MXps1ams7g%3D Occurrence Handle10.1038/378394a0

    Article  PubMed  CAS  Google Scholar 

  58. SA Crone YY Zhao L Fan et al. (2002) ArticleTitleErbB2 is essential in the prevention of dilated cardiomyopathy Nat Med 8 459–465 Occurrence Handle11984589 Occurrence Handle1:CAS:528:DC%2BD38Xjt1Kgtbs%3D Occurrence Handle10.1038/nm0502-459

    Article  PubMed  CAS  Google Scholar 

  59. RD Mass MF Press S Anderson et al. (2005) ArticleTitleEvaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab Clin Breast Cancer 6 240–246 Occurrence Handle16137435

    PubMed  Google Scholar 

  60. LG Dressler DA Berry G Broadwater et al. (2005) ArticleTitleComparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients J Clin Oncol 23 4287–4297 Occurrence Handle15994142 Occurrence Handle1:CAS:528:DC%2BD2MXms12gs7o%3D Occurrence Handle10.1200/JCO.2005.11.012

    Article  PubMed  CAS  Google Scholar 

  61. N Dybdal G Leiberman S Anderson et al. (2005) ArticleTitleDetermination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab Breast Cancer Res Treat 93 3–11 Occurrence Handle16184453 Occurrence Handle1:CAS:528:DC%2BD2MXhtVentLjP Occurrence Handle10.1007/s10549-004-6275-8

    Article  PubMed  CAS  Google Scholar 

  62. EA Perez PC Roche RB Jenkins et al. (2002) ArticleTitleHER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization Mayo Clin Proc 77 148–154 Occurrence Handle11838648 Occurrence Handle10.4065/77.2.148

    Article  PubMed  Google Scholar 

  63. RR Tubbs JD Pettay PC Roche et al. (2001) ArticleTitleDiscrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message J Clin Oncol 19 2714–2721 Occurrence Handle11352964 Occurrence Handle1:STN:280:DC%2BD3M3lsVOlsg%3D%3D

    PubMed  CAS  Google Scholar 

  64. H Yaziji LC Goldstein TS Barry et al. (2004) ArticleTitleHER-2 testing in breast cancer using parallel tissue-based methods JAMA 291 1972–1977 Occurrence Handle15113815 Occurrence Handle1:CAS:528:DC%2BD2cXjs1ajtrk%3D Occurrence Handle10.1001/jama.291.16.1972

    Article  PubMed  CAS  Google Scholar 

  65. YH Ibrahim D Yee (2005) ArticleTitleInsulin-like growth factor-I and breast cancer therapy Clin Cancer Res 11 944s–950s Occurrence Handle15701891 Occurrence Handle1:CAS:528:DC%2BD2MXislWnsrc%3D

    PubMed  CAS  Google Scholar 

  66. Y Lu X Zi Y Zhao et al. (2001) ArticleTitleInsulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 1852–1857 Occurrence Handle11752009 Occurrence Handle1:CAS:528:DC%2BD38XltVWluw%3D%3D Occurrence Handle10.1093/jnci/93.24.1852

    Article  PubMed  CAS  Google Scholar 

  67. S Diermeier G Horvath R Knuechel-Clarke et al. (2005) ArticleTitleEpidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation Exp Cell Res 304 604–619 Occurrence Handle15748904 Occurrence Handle1:CAS:528:DC%2BD2MXhvVCktLw%3D Occurrence Handle10.1016/j.yexcr.2004.12.008

    Article  PubMed  CAS  Google Scholar 

  68. AB Motoyama NE Hynes HA Lane (2002) ArticleTitleThe efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides Cancer Res 62 3151–3158 Occurrence Handle12036928 Occurrence Handle1:CAS:528:DC%2BD38XksVyqs70%3D

    PubMed  CAS  Google Scholar 

  69. R Nahta LX Yuan B Zhang et al. (2005) ArticleTitleInsulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells Cancer Res 65 11118–11128 Occurrence Handle16322262 Occurrence Handle1:CAS:528:DC%2BD2MXht1KjsrrI Occurrence Handle10.1158/0008-5472.CAN-04-3841

    Article  PubMed  CAS  Google Scholar 

  70. S Anastasi G Sala C Huiping et al. (2005) ArticleTitleLoss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin Oncogene 24 4540–4548 Occurrence Handle15856022 Occurrence Handle1:CAS:528:DC%2BD2MXls1Onu70%3D Occurrence Handle10.1038/sj.onc.1208658

    Article  PubMed  CAS  Google Scholar 

  71. AS Clark K West S Streicher et al. (2002) ArticleTitleConstitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells Mol Cancer Ther 1 707–717 Occurrence Handle12479367 Occurrence Handle1:CAS:528:DC%2BD38XlsFSmtLk%3D

    PubMed  CAS  Google Scholar 

  72. FM Yakes W Chinratanalab CA Ritter et al. (2002) ArticleTitleHerceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Res 62 4132–4141 Occurrence Handle12124352 Occurrence Handle1:CAS:528:DC%2BD38XlsV2ltr0%3D

    PubMed  CAS  Google Scholar 

  73. Y Nagata KH Lan X Zhou et al. (2004) ArticleTitlePTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117–127 Occurrence Handle15324695 Occurrence Handle1:CAS:528:DC%2BD2cXns1arsr8%3D Occurrence Handle10.1016/j.ccr.2004.06.022

    Article  PubMed  CAS  Google Scholar 

  74. XF Le FX Claret A Lammayot et al. (2003) ArticleTitleThe role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition J Biol Chem 278 23441–23450 Occurrence Handle12700233 Occurrence Handle1:CAS:528:DC%2BD3sXkslygsLc%3D Occurrence Handle10.1074/jbc.M300848200

    Article  PubMed  CAS  Google Scholar 

  75. R Nahta T Takahashi NT Ueno et al. (2004) ArticleTitleP27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells Cancer Res 64 3981–3986 Occurrence Handle15173011 Occurrence Handle1:CAS:528:DC%2BD2cXksVKns7k%3D Occurrence Handle10.1158/0008-5472.CAN-03-3900

    Article  PubMed  CAS  Google Scholar 

  76. P Nagy E Friedlander M Tanner et al. (2005) ArticleTitleDecreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line Cancer Res 65 473–482 Occurrence Handle15695389 Occurrence Handle1:CAS:528:DC%2BD2MXns1KqsA%3D%3D

    PubMed  CAS  Google Scholar 

  77. SA Price-Schiavi S Jepson P Li et al. (2002) ArticleTitleRat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance Int J Cancer 99 783–791 Occurrence Handle12115478 Occurrence Handle1:CAS:528:DC%2BD38XksVajs78%3D Occurrence Handle10.1002/ijc.10410

    Article  PubMed  CAS  Google Scholar 

  78. WJ Kostler G Hudelist W Rabitsch et al. (2006) ArticleTitleInsulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer J Cancer Res Clin Oncol 132 9–18 Occurrence Handle16184380 Occurrence Handle10.1007/s00432-005-0038-8 Occurrence Handle1:CAS:528:DC%2BD2MXht1Gnu7jP

    Article  PubMed  CAS  Google Scholar 

  79. H Meden A Beneke T Hesse et al. (2001) ArticleTitleWeekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study Anticancer Res 21 1301–1305 Occurrence Handle11396203 Occurrence Handle1:CAS:528:DC%2BD3MXksVyitbw%3D

    PubMed  CAS  Google Scholar 

  80. S Gori M Colozza AM Mosconi et al. (2004) ArticleTitlePhase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer Br J Cancer 90 36–40 Occurrence Handle14710203 Occurrence Handle1:CAS:528:DC%2BD2cXhtFKntQ%3D%3D Occurrence Handle10.1038/sj.bjc.6601485

    Article  PubMed  CAS  Google Scholar 

  81. JP Raff L Rajdev U Malik et al. (2004) ArticleTitlePhase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer Clin Breast Cancer 4 420–427 Occurrence Handle15023243 Occurrence Handle1:CAS:528:DC%2BD2cXjtlKisL0%3D

    PubMed  CAS  Google Scholar 

  82. MD Pegram DJ Slamon (1999) ArticleTitleCombination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity Semin Oncol 26 89–95 Occurrence Handle10482199 Occurrence Handle1:CAS:528:DyaK1MXmt1Sitr8%3D

    PubMed  CAS  Google Scholar 

  83. H Burris Suffix3rd D Yardley S Jones et al. (2004) ArticleTitlePhase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer J Clin Oncol 22 1621–1629 Occurrence Handle15117984 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWmu7k%3D Occurrence Handle10.1200/JCO.2004.08.065

    Article  PubMed  CAS  Google Scholar 

  84. JA O'Shaughnessy S Vukelja T Marsland et al. (2004) ArticleTitlePhase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer Clin Breast Cancer 5 142–147 Occurrence Handle15245619 Occurrence Handle10.3816/CBC.2004.n.019

    Article  PubMed  Google Scholar 

  85. G Fountzilas C Christodoulou D Tsavdaridis et al. (2004) ArticleTitlePaclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) Cancer Invest 22 655–662 Occurrence Handle15581045 Occurrence Handle1:CAS:528:DC%2BD2cXosFShsro%3D Occurrence Handle10.1081/CNV-200032980

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eriko Tokunaga.

About this article

Cite this article

Tokunaga, E., Oki, E., Nishida, K. et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 11, 199–208 (2006). https://doi.org/10.1007/s10147-006-0575-4

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-006-0575-4

Key words

Navigation